Design of surface-modified poly(d,l-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone

Journal of Controlled Release

Volumn 122, Issue 1, 2007, Pages 24-30

  Choi, Sung Wook ^a   Kim, Jung Hyun ^a  

^a Yonsei University   (South Korea)

Author keywords

Alendronate; Bone targeted drug delivery; Dialysis method; mPEG PLGA block copolymer; PLGA nanoparticles

Indexed keywords

ALENDRONATES; CARBODIIMIDE CHEMISTRY; RETICULOENDOTHELIAL SYSTEMS (RES);

ADSORPTION; BLOCK COPOLYMERS; BONE; DIALYSIS; DRUG DELIVERY; HYDROXYAPATITE; POLYETHYLENE GLYCOLS; SURFACE TREATMENT;

NANOPARTICLES;

ALENDRONIC ACID; HYDROXYAPATITE; MACROGOL; NANOPARTICLE; POLY(DEXTRO,LEVO LACTIDE CO GLYCOLIDE); POLYGLACTIN; UNCLASSIFIED DRUG;

ARTICLE; BONE DISEASE; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; MOLECULAR WEIGHT; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM;

ADSORPTION; ALENDRONATE; BONE AND BONES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DURAPATITE; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR WEIGHT; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 34548033267     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.06.003     Document Type: Article

References (31)

1. Fahmy T.M., Fong P.M., Goyal A., and Saltzman M. Targeted for drug delivery. Materials Today 8 8 (2005) 18-26
2. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., Hennekens C., Rosner B., and Speizer F.E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332 (1995) 1589-1593
3. Raisz L.G. The osteoporosis revolution. Ann. Intern. Med. 126 (1997) 458-462
4. Wang D., Miller S.C., Kopečková P., and Kopeček J. Bone-targeting macromolecular therapeutics. Adv. Drug Deliv. Rev. 57 (2005) 1049-1076
5. Cho C.S., Cho K.Y., Park I.K., Kim S.H., Sasagawa T., Uchiyama M., and Akaike T. Receptor-mediated delivery of all trans-retinoic acid to hepatocyte using poly(l-lactic acid) nanoparticles coated with galactose-carrying polystyrene. J. Control. Release 77 (2001) 7-15
6. Russell-Jones G.J., Arthur L., and Walker H. Vitamin B12-mediated transport of nanoparticles across Caco-2 cells. Int. J. Pharm. 179 (1999) 247-255
7. Stella B., Arpicco S., Peracchia M.T., Desmaele D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., and Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 89 (2000) 1452-1464
8. Owen III D.E., and Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307 (2006) 93-102
9. Alexandrisdis P., Holzwarth J.F., and Hatton T.A. Micellization of poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) triblock copolymers in aqueous solutions. Thermodynamics of copolymer association. Macromolecules 27 (1994) 2414-2425
10. Kim S.Y., Shin I.G., Lee Y.M., Cho C.S., and Sung Y.K. Methoxy poly(ethylene glycol) and e{open}-caprolactone amphiphilic block copolymeric micelle containing indomethacin.: II. Micelle formation and drug release behaviours. J. Control. Release 51 (1998) 13-22
11. Kwon G.S., Naito M., Yokoyama M., and Okano T. Physical entrapment of adriamycin in AB block copolymer micelles. Pharm. Res. 12 (1995) 192-195
12. Lasic D.D. Mixed micelles in drug delivery. Nature 355 (1992) 279-280
13. Kim I.S., Jeong Y.I., Cho C.S., and Kim S.H. Core-shell type polymeric nanoparticles composed of poly(l-lactic acid) and poly(N-isopropylacrylamide). Int. J. Pharm. 211 (2000) 1-8
14. Valuev I.L., Chupov V.V., and Valuev L.I. Chemical modification of polymers with physiologically active species using water-soluble carbodiimides. Biomaterials 19 (1998) 41-43
15. Oh J.E., Nam Y.S., Lee K.H., and Park T.G. Conjugation of drug to poly(d,l-lactide-co-glycolic acid) for controlled release from biodegradable microspheres. J. Control. Release 57 (1999) 269-280
16. Gil L., Han Y., Opas E.E., Rodan G.A., Ruel R., Seedor J.G., Tyler P.C., and Young R.N. Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg. Med. Chem. 7 (1999) 901-919
17. Hirabayashi H., Takahashi T., Fujisaki J., Masunaga T., Sato S., Hiroi J., Tokunaga Y., Kimura S., and Hata T. Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on Osteotropic Drug Delivery System (ODDS). J. Control. Release 70 (2001) 183-191
18. Hirabayashi H., and Fujisaki J. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin. Pharmacokinet. 42 (2003) 1319-1330
19. Orme M.W., and Labroo V.M. Synthesis of h-estradiol-3-benzoate-17-(succinyl-12a-tetracycline): a potential bone-seeking estrogen. Bioorg. Med. Chem. Lett. 4 11 (1994) 1375-1380
20. Uludag H., and Yang J. Targeting systemically administered proteins to bone by bisphosphonate conjugation. Biotechnol. Prog. 18 (2002) 604-611
21. Willson T.M., Charifson P.S., Baxter A.D., and Geddie N.G. Bone-targeted drugs: 1. Identification of heterocycles with hydroxyapatite affinity. Bioorg. Med. Chem. Lett. 6 9 (1996) 1043-1046
22. Willson T.M., Kenke B.R., Momtahen T.M., Garrision D.T., Moore L.B., Geddie N.G., and Baer P.G. Bone targeted drugs: 2. Synthesis of estrogens with hydroxyapatite affinity. Bioorg. Med. Chem. Lett. 6 (1996) 1047-1050
23. Yokogawa K., Miya K., Sekido T., Higashi Y., Nomura M., Fujisawa R., Morito K., Masamune Y., Waki Y., Kasugai S., and Miyamoto K. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 142 (2001) 1228-1233
24. Wang D., Miller S., Sima M., Kopečková P., and Kopeček J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjugate Chem. 14 (2003) 853-859
25. Kopeček J., Kopečková P., Minko T., and Lu Z.R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50 1 (2000) 61-81
26. Heald C.R., Stolnik S., Kujawinski K.S., De Matteis C., Garnett M.C., Illum L., Davis S.S., Purkiss S.C., Barlow R.J., and Gellert P.R. Poly(lactic acid)-poly(ethylene oxide) (PLA-PEG) nanoparticles: NMR studies of the central solidlike PLA core and the liquid PEG corona. Langmuir 18 (2002) 3669-3675
27. Riley T., Stolnik S., Heald C.R., Xiong C.D., Garnett M.C., Illum L., Davis S.S., Purkiss S.C., Barlow R.J., and Gellert P.R. Physicochemical evaluation of nanoparticles assembled from poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) block copolymers as drug delivery vehicles. Langmuir 17 (2001) 3168-3174
28. Lacey, Jr. J.V., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., Schatzkin A., and Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. J. Am. Med. Assoc. 288 (2002) 334-341
29. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J. Am. Med. Assoc. 288 (2002) 321-333
30. 6 conjugation. J. Bone Miner. Res. 15 (2000) 936-943
31. Fleisch H. Diphosphonates: history and mechanism of action. Metab. Bone Dis. Relat. Res. 54 (1978) 265-272